Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Shortages of Moderna COVID-19 boosters seen in US

Some of the nation's pharmacies are reporting shortages of Moderna Inc.’s new bivalent booster shot for COVID-19 as one factory used in producing the vaccine remains offline following a safety inspection.

Tribune News Service

Norton, Baptist begin offering new COVID-19 boosters

WEKU

3 Healthcare Stocks Under $100 to Buy Right Now

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK),…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

The only party not getting heartburn over GSK demerger is the lawyers

The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years

The Guardian - UK

Hero nurse who administered first Covid jab in UK walks behind Queen's coffin

Modern matron nurse May Parsons injected the first ever dose of the Pfizer vaccine into 90-year-old grandmother Maggie Keenan on December 8, 2020, at Coventry Hospital

Daily Mirror

Brazil approves Pfizer vaccine for children as young as six months

Brazilian national health regulator Anvisa has approved the COVID-19 vaccine produced by Pfizer and BioNTech for children aged between six months and four years, the government body said in a statement Friday night.

Reuters

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Commentary: Will vaccine fatigue affect how many people get the bivalent booster?

Pfizer’s and Moderna’s bivalent boosters, which are now available to many age groups, offer protection against the original COVID-19 virus plus the BA.4 and BA.5 omicron subvariants. Is the nation ready for yet another COVID-19 vaccine shot?

Chicago Tribune

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Benzinga

Is the new omicron vaccine worth it?

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Salon

Commentary: Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

Tribune News Service

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

StockNews.com

EU Regulator Backs Pfizer's BA.4/5-Adapted COVID Booster

The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant. The latest recommendation is for a so-called bivalent vaccine developed by Pfizer and BioNTech, which targets BA.4/5 as well…

Asharq Al-Awsat

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

EU regulator clears Pfizer-BioNTech's tweaked COVID booster

The European Medicines Agency has recommended the authorization of a tweaked booster dose of the Pfizer-BioNTech coronavirus vaccine that includes protection against two of the latest versions of omicron, as countries look to bolster their immunization programs ahead of winter

Inverse

Covid-19 boosters: Immunologists answer 5 key questions about the new shots

What is different about the updated booster shots? Two scientists offer their expertise to answer five questions about the shots.

Benzinga

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Benzinga

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

Zenara launches generic version of Pfizer Covid drug Paxlovid

Sets MRP at ₹5,200 for a box of 20 Nirmatrelvir tablets, 10 tablets of Ritonavir

The New Daily

Get booster shots, doctors warn, as Australia all but declares COVID-19 dead

As social protections are abandoned, only 71.6 per cent of Australians aged 16 years and over have had their latest COVID vaccine booster.

Tribune News Service

COVID rebound symptoms, positive tests after Paxlovid are more common than reported, study says

Resurgence of COVID-19 symptoms in patients treated with Pfizer Inc.’s Paxlovid appeared far more common than has been reported, and rebounding patients still risked spreading the disease, doctors said in a report on a series of cases in a top medical journal.

Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Chicago Sun-Times

No, COVID-19 isn’t winding down, scientists say, predicting it’ll be around the rest of our lives

Even with new boosters, experts predict the scourge that’s already lasted longer than the 1918 flu pandemic will linger far into the future. Here’s why.

Benzinga

Pfizer Whale Trades For September 07

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 11 strange trades.

Los Angeles Times

Potential to mix up omicron booster with conventional vaccine raises concerns

Experts are voicing concerns about the potential for vaccine providers to mix up the omicron booster vial with those used for conventional vaccines.

1 … 38 39 40 41

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.